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ate the efficacy and safety of new anticoagulants in the treatment of AF. Methods: 
Health Technology Assessment of multiple technologies. We searched the electronic 
databases Cochrane Library, CRD, Pubmed, Embase and Lilacs, to search for the best 
available evidence assessing the new oral anticoagulants, compared with warfa-
rin in patients with AF. Results: Three randomized controlled trials evaluating 
dabigatran (110mg e 150mg), rivaroxaban 20mg and apixaban 5mg were included, 
all of them compared with warfarin. In this regard, dabigatran 110mg was associ-
ated with similar rates of stroke or systemic embolism and with a 20% relative risk 
reduction (RRR) of major hemorrhage compared with warfarin. Dabigatran 150mg 
was associated with a 34% RRR of stroke or systemic embolism and similar rates 
of major hemorrhage. Rivaroxaban 20mg was associated with similar rates of the 
primary efficacy and safety outcomes. Finally, apixaban was associated with a 21% 
RRR of stroke or systemic embolism and with 31% RRR of major bleeding compared 
with warfarin. ConClusions: There is strong evidence supporting these new tech-
nologies, especially regarding safety. Further studies are needed to support decision 
making, especially with regards to cost-effectiveness issues.
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objeCtives: Positron Emission Tomography (PET) might be useful for cancer staging 
and follow-up. The objetive was to assess the available evidence on efficacy, safety 
and coverage policies for use of PET in oncology. Methods: A bibliographic search 
was carried in PubMed, DARE, NHS EED, in health technology assessment (HTA) 
agencies and health insurers. Priority was given to systematic reviews; randomized 
clinical trials (RCTs); HTA; clinical practice guidelines (CPGs) and coverage policies 
(CPs). Results: Thirty-seven systematic reviews, 3 RCTs and 32 observational stud-
ies, 51 CPGs, 15 HTAs and 28 CPs were included. Breast Cancer (17 studies):There 
is no evidence of its use as routine practice. Some CPGs and CPs recommend it for 
suspicious images that could not be clarified through conventional studies. PET is 
not recommended for axillary staging or neodadyuvant response prediction. Lung 
Cancer (44 studies):The accuracy for lung nodule is similar to conventional methods. 
Most CPGs do not recommend the use of PET for lung cancer staging except in some 
non-small cell lung cancer with previous negative tests for metastasis. Colorectal 
Cancer (20 studies): There is no evidence of its use as routine practice. It might be 
used in patients with suspected recurrence and non-conclusive images. Genitourinary 
Tumors (70 studies): PET might be associated with changes in diagnosis or therapeutic 
only in specific cases, such as ovarian cancer with suspected recurrence and nor-
mal conventional images, in residual tumors due to seminoma and cervical cancer 
recurrence eligible for curative treatment. Primary Tumors of the Central Nervous 
System (15 studies):PET is not recommended as routine practice. CPGs, RCTs and CPs 
recognize its usefulness for differential diagnosis between relapse and radionecro-
sis. ConClusions: There is no evidence to support the use of PET in cancer patients 
as routine practice. At present, its use should be restricted to specific patients.
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objeCtives: To evaluate the efficacy, safety and cost-effectiveness data of lipid 
formulations of amphotericin B to establish which should be used for the treatment 
of systemic fungal infections in patients with HIV/AIDS in Brazil. Methods: We 
searched The Cochrane Library, Centre for Reviews and Dissemination, Tripdatabase, 
Medline and LILACS databases aiming to find systematic reviews (SRs) and eco-
nomic evaluations (EE) comparing liposomal amphotericin B (L-AmB) or ampho-
tericin B lipid complex (ABLC). Health Technology Assessments (HTA) were searched 
on agencies websites. Quality of the evidence and strength of recommendation 
were evaluated using the GRADE system. Results: We selected five SRs, in which 
one evaluated only safety data, and two economic evaluations. Four SRs were clas-
sified as poor quality and the strength of recommendation was considered weak 
in favor of L-AmB in all studies. In general there were no statistically significant 
differences in terms of survival and response to treatment (p< 0,05). However, L-AmB 
was associated with a lower risk of nephrotoxicity and increased serum creatinine. 
The two economic studies included had conflicting results. In the cost-minimization 
study there was no difference in total costs of the therapies, but the daily cost of 
acquisition and concomitant antifungal therapy and adverse events were lower 
for ABLC (0,002 and 0,027). The incremental cost-effectiveness analysis favored the 
L-AmB (€ 41734 vs. € 51724). Both studies showed important limitations and there 
were no studies considering the Brazilian context. ConClusions: Considering all 
the studies found, as well as their limitations, there is a lack of evidence to support 
the spread use of L-amB in patients with HIV/AIDS affected by fungal infections, 
unless strictly in cases where patients have abnormal renal function. Also, L-AmB 
could be used in case of intolerance to conventional amphotericin B.
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ernment in better health system performance, as well as the positive effect of 
increased public investment in health over the decade in health indicators and 
process insurance in the last 5 years. ConClusions: The results suggest a 
positive effect of central government spending on health and a negative effect 
of income inequality and margination index on maternal and infant mortali-
ties, clearly mediated by socioeconomic factors characteristic of each state. 
This methodological approach is proposed to evaluate the relationships of the 
different levels of functioning of a health system and the dynamics with the 
social determinants of these levels.
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objeCtives: As follow-up to prior work, investigate what evidence is required 
for reimbursement and prescribing of biosimilar drugs from four key therapy 
areas in six Latin American countries (Argentina, Brazil, Chile, Colombia, 
Mexico and Venezuela). Explore how these requirements may correspond to 
the regulatory pathways across the different countries. Methods: Conduct 
secondary research to determine any recent changes to biosimilar regulation in 
the six studied countries. Conduct targeted primary research with payers and 
physicians in the six counties exploring: 1) The therapy areas that payers and 
physicians consider most attractive for biosimilars; 2) The baseline evidence 
(bioequivalence, comparative trial data, extrapolation of indications, etc.) that 
stakeholders require across the key therapy areas and across countries; 3) The 
level of discount, below the branded equivalent, that payers and physicians 
would require to consider biosimilars for access or to prescribe to their patients; 
4) The expected access level and prescribing decisions for those biosimilars that 
meet these evidence and discount criteria; and 5) The degree to which payer 
and physician evidence expectations for biosimilars map to our understanding 
of the evolution of biosimilar regulatory environment. Results: Public payers 
across the region see biosimilars as an opportunity to provide broader access to 
needed medications, although some stakeholders are more receptive than oth-
ers and have lower requirements to prove comparability. Clinicians in general 
have concerns about safety and efficacy, however, their willingness to prescribe 
biosimilars correlates inversely with the degree of access and affordability of 
the branded agents. ConClusions: The regulatory and access environment for 
biosimilars in Latin America can be expected to be more favorable than in the 
US but not too dissimilar from Europe. However there are systematic differences 
across countries and therapy areas.
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objeCtivos: El Streptococcus pneumoniae causa una importante morbilidad y 
mortalidad a nivel mundial, tanto en niños como en adultos. El objetivo de este 
análisis es estimar la costo-efectividad de la vacuna conjugada 13-valente (PCV13) 
vs la vacuna neumocócica polisacárida 23-valente (PPSV23) y vs no vacunación en 
los adultos de alto riesgo (inmunocomprometidos) > 50 años en Colombia, desde 
la perspectiva del tercero pagador. MetodologíAs: Se adaptó un modelo de 
Markov con horizonte de tiempo de la expectativa de vida y tasa de descuento 3% 
anual. Los comparadores fueron PCV13, PPSV23 y no vacunación (NV), cobertura 
estimada del 70%; revacunación a los 5 años con PPSV23 para > 65 años según 
criterios del CDC. Se utilizó la población > 50 años de alto riesgo en Colombia. 
Las probabilidades de transición, incidencia de enfermedades y efectividades de 
las vacunas fueron extraídas de la literatura (para PCV13 se utilizaron datos de 
PCV7 ajustados por inmunosenescencia), los costos médicos fueron proveídos por 
una EPS de cobertura nacional; los precios de las vacunas fueron tomados de la 
OPS para 2013. Los costos se presentan en US$ 2013. Las medidas de efectividad 
fueron número de casos evitados de enfermedad neumocócica invasiva – ENI 
(meningitis y bacteremia), neumonía invasiva, muertes y años de vida ganados 
(AVG). ResultAdos: Vacunar con PCV13 vs NV y PPSV23 previene 4.389 y 4.134 
casos de ENI; 2594 casos de neumonía invasiva y 550 y 536 muertes respectiva-
mente. PCV13 genera 199 AVG más que PPSV23 y 4.712 AVG más que NV. El ahorro 
total esperado (vacunación + costos médicos) con PCV13 fue US$18,254,171 vs NV 
y US$26,204,251 vs PPSV23. ConClusiones: Vacunar adultos inmunocompro-
metidos > 50 años con PCV13 en Colombia es una alternativa costo-ahorradora en 
comparación con NV y con PPSV23 (US$12.57 y US$18.08 ahorrados por paciente 
respectivamente). Los hallazgos de este estudio soportan una toma de decisión 
a favor de PCV13.
HealTH TecHnology assessmenT sTuDies
HT1
efficacy anD safeTy of new anTicoagulanTs in THe TReaTmenT of 
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Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. 
Patients with AF have a 4-5 times larger risk of stroke than age-matched controls. 
Anticoagulation with warfarin is currently the standard of care but the requirement 
for routine monitoring and drug and food interactions, makes its use is suboptimal. 
New anticoagulants were developed to eliminate these barriers and the results are 
promising. However, the incorporation of these technologies within the Brazilian 
Unified Health System (SUS) demands proper consideration. objeCtives: To evalu-
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análisis de sensibilidad en los escenarios incluidos, demostrando robustez de los 
resultados del modelo planteado. ConClusiones: El uso de las PTRI como prueba 
inicial de tamizaje para detectar y tratar gestantes con sífilis es costo-efectivo en 
Colombia, evitando casos de sífilis congénita y sus consecuencias.
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intRoduCCión: El Trastorno Depresivo Mayor (TDM) es la comorbilidad psiquiátrica 
de mayor prevalencia en personas con VIH y ocasiona menor adherencia al TARGA, 
lo que a su vez repercute en una mayor progresión de la enfermedad e incrementa 
los costos de atención para el sistema. objeCtivos: Realizar un estudio de costo-
efectividad de intervenciones para el manejo TDM en una cohorte hipotética de 
pacientes mexicanos con VIH bajo TARGA, desde el punto de vista del Sistema de 
Salud público en México. MetodologíAs: Estudio de costo-efectividad medi-
ante un modelo Markov, ciclosmensuales, para estimar la esperanza de vida por 
alternativa evaluada, la ocurrencia de sucesos y costos asociados, en pacientes 
que se encuentran por iniciar TARGA. El modelo está compuesto por los siguientes 
estados de salud: padecer VIH, estar bajo TARGA y presentar TDM; padecer VIH, 
estar bajo TARGA y no presentar TDM; muerte. Los comparadores incluidos son 
el uso de antidepresivos, la Terapia Cognitivo Conductual (TCC), combinación de 
ambas, ninguna intervención. Las probabilidades para la matriz de transición se 
obtuvieron de la literatura; y los costos médicos directos institucionales que se 
midieron son: antidepresivos, consultas especialistas, tratamiento de VIH/SIDA. Se 
corroboró la información con opinión de expertos. El horizonte temporal evaluado 
es la sobrevida del paciente. La tasa de descuento es 5%. Se realizó un análisis de 
costo efectividad incremental y un análisis de sensibilidad. ResultAdos: La TCC 
fue la intervención más costo-efectiva. Las 3 alternativas resultan en un costo por 
año de vida ganado menor a un PIB per cápita y presentan una ganancia en salud 
similar (2.77 años). Costos: TCC ($ 22,622.412); antidepresivos ($24,659.7538) y para 
la combinación de tratamientos ($24,790.722). El análisis de sensibilidad demostró 
la robustez del modelo. ConClusiones: El proporcionar tratamiento contra el 
TDM en pacientes con VIH bajo TARGA ofrece una ganancia en salud y resulta costo-
efectivo para el sistema.
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objeCtivos: Aun sigue siendo controversial el manejo del lactante febril (LFSF) sin 
foco entre uno a tres meses. La introducción de la vacunación contra neumococo ha 
reducido las tasas de bacteriemia oculta y alterado la utilidad de los tests disponi-
bles para detección de infección bacteriana severa (IBS) en LFSF. El objetivo de este 
estudio fue determinar la costo-efectividad de tres pruebas para la detección de IBS 
en LFSF. MetodologíAs: Se diseñó un modelo de costo-efectividad utilizando la 
técnica de análisis de decisiones, bajo la perspectiva del financiador (Obra Social) e 
incorporando los costos directos del tratamiento, hospitalización y diagnóstico; para 
comparar la razón de costo efectividad incremental entre la procalcitonina, proteína 
C reactiva y la escala de Rochester en una cohorte hipotética de 10.000 niños entre 
1 a 3 meses con diagnóstico de LFSF. ResultAdos: La proteína C reactiva resulta 
en un costo de AR$5341 por caso correctamente diagnosticado, frente a AR$5376. 
El costo por cada caso correctamente diagnosticado con la procalcitonina frente 
a la proteína C reactiva fue de AR$6127. La proteína C reactiva permanece siendo 
la estrategia más costo efectiva independiente de los valores dentro de los rangos 
declarados que puedan tomar los costos de internación y costo de la proteína C 
reactiva; así como los valores dentro del rango establecido de probabilidad de IBS, 
IBS por neumococo y efectividad vacunal. ConClusiones: La proteína C reactiva 
constituye la estrategia más costo efectiva en la Argentina para la detección de la IBS 
en lactantes que acuden con SFSF. Sin embargo dado las moderadas proporciones 
de casos correctamente diagnosticados (< 80%) aun existentes; estas pruebas deben 
ser interpretadas dentro del contexto clínico del paciente y no como método único 
para la toma de decisiones terapéuticas.
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objeCtives: Differential pricing (DP) on the basis of countries’ purchasing power 
has been recommended by the WHO to secure more affordably priced medicines. 
However, in developing counties (DC) many innovative drugs have similar or even 
higher prices than in high-income countries (HIC). We conducted a cost-effectiveness 
objetivos: Avaliar e comparar a eficácia e a segurança do ranibizumabe e do 
bevacizumabe para o tratamento da Degeneração Macular Relacionada a Idade 
(DMRI). Métodos: Realizou-se uma revisão sistemática / overview utilizando as bases 
The Cochrane Library, Centre for Reviews and Dissemination, Medline e LILACS com o obje-
tivo de encontrar estudos que comparassem ranibizumabe ou bevacizumabe com 
qualquer outra opção terapêutica para o tratamento da DMRI. Os estudos de avaliações 
econômicas foram buscados em sites da Rede Brasileira de Avaliação de Tecnologias e 
Saúde (REBRATS), no National Institute for Clinical Excellence and Health, Health Technology 
Assessment Programme eCanadian Agency for Drugs and Technologies in Health. ResultAdos: 
Foram identificados 643 títulos e destes, 14 foram incluídos sendo 5 revisões sistemáticas 
e 9 avaliações econômicas. A síntese dos resultados das revisões sistemáticas mostrou 
que ambos os medicamentos são eficazes, isso é, evitam a perda progressiva da visão 
e/ou aumentam a acuidade visual sobretudo quando comparados aos demais trata-
mentos disponíveis para a DMRI. Não foram encontrados estudos que comparassem 
diretamente a eficácia do ranibizumabe versus o bevacizumabe o que comprometeu 
uma possível avaliação da superioridade clínica entre eles. Por outro lado, as avaliações 
econômicas apontaram que a vantagem de um medicamento em relação ao outro está 
na diferença dos custos. O ranibizumabe em todos os cenários estudados foi mais caro 
e para torná-lo custo-efetivo é necessário que seu preço diminua. Já o bevacizumabe, 
possui eficácia equivalente e um custo inferior que provavelmente está relacionado 
a sua forma de administração - uma ampola para mais de um paciente - o que tem 
ocasionado uma discussão quanto à sua utilização off label no Brasil. ConClusões: 
Recomenda-se a utilização do ranibizumabe ou do bevacizumabe para a forma úmida 
da DMRI em pacientes maiores de 50 anos de idade.
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objeCtives: Herpes zoster (HZ) is caused by the re-activation of latent varicella-
zoster virus (VZV) and is characterized by unilateral, vesicular cutaneous eruptions, 
acute neuritis and post-herpetic neuralgia (PHN). To date, data on HZ associated 
pain (ZAP) and its impact on quality of life (QoL) in Argentina are scarce. This study 
assesses the burden of illness associated with HZ in Argentina in a real-life clini-
cal setting. Methods: This was a prospective, observational, single-cohort study. 
Patients were enrolled at various time points during the course of a zoster episode 
and were followed for ≤ 6 months. ZAP was assessed with the Initial Zoster Impact 
Questionnaire and the Zoster Brief Pain Inventory, while QoL was assessed with the 
EQ-5D instrument using the Hispanic preference weights. Results: A total of 96 
HZ patients were enrolled with a mean (SD) age of 70.14 (10.7) years and 64 (66.7%) 
being females. At baseline, mean (SD) time since rash onset was 15.92 (16.9) days. 
Prior to rash onset (prodrome phase), a significant proportion (59.4%) of patients 
experienced a worst pain score of ≥ 5. ZAP was reported by 92 (95.8%) patients at 
baseline. Mean (SD) worst pain score decreased from 5.47 (3.1) at baseline to 2.94 
(3.0) at 30 days and 0.21 (0.7) at 180 days. PHN (worst pain ≥ 3 after ≥ 90 days since 
rash onset) was experienced by 11 (11.5%) patients. The mean (SD) EQ-5D score sig-
nificantly decreased (P< 0.001) from 0.84 (0.10) before rash onset to 0.63 (0.20) after 
rash onset, increasing thereafter, showing significant (P< 0.05) QoL deterioration 
up to 60 days of follow-up. ConClusions: HZ pain can significantly reduce QoL 
and ability to perform daily activities of people living in Argentina highlighting the 
importance of early intervention or prevention. These findings are consistent with 
observational studies in other countries.
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objeCtivos: Evaluar la costo-efectividad del uso de pruebas treponémicas 
rápidas inmunocromatográficas (PTRI) para el tamizaje de Sífilis gestacional en 
Colombia. MetodologíAs: Se desarrolló un árbol de decisiones en una cohorte 
hipotética de pacientes gestantes, las alternativas consideradas fueron: manejo con-
vencional usando prueba no treponémica (VDRL) seguida de treponémica (FTA-ABS) 
frente a una propuesta usando PTRI, Inicio de tratamiento a gestantes positivas y 
prueba confirmatoria con VDRL. Se consideraron varios escenarios: Gestantes tami-
zadas antes de las 24 semanas y a contactos (GT1); Gestantes tamizadas antes de las 
24 semanas sin contactos (GT2); Gestantes tamizadas antes de las 34 semanas con y 
sin contactos respectivamente (GT3), (GT4). La perspectiva fue la del tercer pagador 
y el horizonte temporal 10 meses. Se incluyeron los costos de los medicamentos, la 
estancia hospitalaria, los eventos adversos secundarios al uso de los medicamentos, 
las valoraciones médicas y paraclínicos en su seguimiento. Se realizó análisis de 
sensibilidad determinístico de las variables con mayor incertidumbre. El modelo fue 
desarrollado por un equipo de profesionales de la salud Epidemiólogos, Ginecólogos, 
con asesoría de especialistas en Economía de la Salud en el año 2012. ResultAdos: 
La estrategia propuesta PRTI-VDRL presenta una dominancia absoluta sobre el 
manejo convencional VDRL-FTABS con una disminución de costos de US 210 y un 
aumento de efectividad del 0.18 (18% más de casos evitados de sífilis congénita) en el 
escenario GT1. Esta dominancia absoluta se observó también en los otros escenarios 
estudiados (GT2, GT3, GT4). El resultado de dominancia se mantuvo al realizar el 
